Healios AG Announces Addition of Anna Walz to Board of Directors
April 12, 2022 14:00 ET
|
Healios AG
BASEL, Switzerland, April 12, 2022 (GLOBE NEWSWIRE) -- Healios AG, a MedTech company focused on developing and validating digital biomarkers since 2014, announced that Anna Walz has been appointed...
Inventiva annonce la présentation d’un abstract scientifique lors de la prochaine International Conference on Fatty Liver
April 07, 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 7 avril 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites...
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
April 07, 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
April 06, 2022 09:00 ET
|
Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
March 08, 2022 02:00 ET
|
INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
March 08, 2022 02:00 ET
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Reprocessed Medical Devices Market ($4.5Bn by 2028) Growth Forecast at 14.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
March 01, 2022 02:40 ET
|
Vantage Market Research
WASHINGTON, March 01, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Reprocessed Medical Devices Market finds that increasing the adoption of Reprocessed Medical...
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
February 15, 2022 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
Dental Care Medical Ceramics Market to Grow at a CAGR of Nearly 6% by 2031: Comprehensive Research by Fact.MR
February 15, 2022 15:30 ET
|
FACT.MR
ROCKVILLE, Md., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rise in application in various medical fields such as dental implants, bone implants, and kidney dialysis machines and equipment has been fuelling...
Positive Results for Lipid inCode® in NHS Clinical Study
February 15, 2022 02:00 ET
|
GENinCode Plc
OXFORD, England, Feb. 15, 2022 (GLOBE NEWSWIRE) -- GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the successful completion...